PA

Perceptive Advisors Portfolio holdings

AUM $6.66B Turnover 32.23%
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+43.17%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.56B
AUM Growth
+$116M
Cap. Flow
-$205M
Cap. Flow %
-5.76%
Top 10 Hldgs %
45.81%
Holding
127
New
13
Increased
20
Reduced
25
Closed
31
Avg Time Held Equity + Options
2.1 years
Top 10 Avg Time Held Equity + Options
1.5 years
Top 20 Avg Time Held Equity + Options
1.5 years
Avg Time Held Equity only
2.2 years
Top 10 Avg Time Held Equity only
1.5 years
Top 20 Avg Time Held Equity only
1.5 years

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$79.7M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$45.9M
3
PCVX icon
Vaxcyte
PCVX
+$45.9M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$39.2M
5
ACRV icon
Acrivon Therapeutics
ACRV
+$38.2M

Top Sells

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$158M
2
RLMD icon
Relmada Therapeutics
RLMD
+$88.2M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$43.3M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$38.4M
5
EW icon
Edwards Lifesciences
EW
+$27.3M

Sector Composition

Rank Sector Weight
1 Healthcare 97.34%
2 Miscellaneous 2.57%
3 Financials 0.08%
4 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
EW icon
101
Edwards Lifesciences
EW
$49.8B
– –
-330,000
Closed -$27.3M –
FULC icon
102
Fulcrum Therapeutics
FULC
$280M
– –
-294,118
Closed -$2.38M –
HCAT icon
103
Health Catalyst
HCAT
$131M
– –
-389,962
Closed -$3.78M –
HYPR icon
104
Hyperfine
HYPR
$84.8M
– –
-927,388
Closed -$751K –
PYXS icon
105
Pyxis Oncology
PYXS
$149M
– –
-1,528,812
Closed -$3.01M –
RCUS icon
106
Arcus Biosciences
RCUS
$2.87B
– –
-666,477
Closed -$17.4M –
RLMD icon
107
Relmada Therapeutics
RLMD
$346M
– –
-2,383,478
Closed -$88.2M –
RVMD icon
108
Revolution Medicines
RVMD
$41.5B
– –
-310,500
Closed -$6.12M –
SRZN icon
109
Surrozen
SRZN
$279M
– –
-401
Closed -$12K –
WGS icon
110
GeneDx Holdings
WGS
$2.05B
– –
-151,515
Closed -$4.39M –
YMAB icon
111
DELISTED
Y-mAbs Therapeutics
YMAB
– –
-212,018
Closed -$3.06M –
NARI icon
112
DELISTED
Inari Medical, Inc. Common Stock
NARI
– –
-70,000
Closed -$5.08M –
PSTX icon
113
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
– –
-750,000
Closed -$2.65M –
SNCE
114
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
– –
-75,000
Closed -$2.42M –
NEPT
115
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
– –
-1,429
Closed -$87K –
ICVX
116
DELISTED
Icosavax, Inc. Common Stock
ICVX
– –
-93,591
Closed -$296K –
SGEN
117
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-316,544
Closed -$43.3M –
SONX
118
DELISTED
Sonendo, Inc.
SONX
– –
-612,204
Closed -$655K –
RETA
119
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-100,000
Closed -$2.51M –
PRVB
120
DELISTED
Provention Bio, Inc. Common Stock
PRVB
– –
-110,728
Closed -$498K –
AGRX
121
DELISTED
Agile Therapeutics
AGRX
– –
-10,647
Closed -$158K –
CNCE
122
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
– –
-2,150,641
Closed -$14.4M –
TCDA
123
PUT
DELISTED
Tricida, Inc. Common Stock
TCDA
– –
-500,000
Closed -$5.24M –
QTNT
124
DELISTED
Quotient Limited Ordinary Shares
QTNT
– –
-405,020
Closed -$2.43M –
CCXI icon
125
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-192,680
Closed -$9.95M –
2 3 4
5
6

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q4 2022 Portfolio in Review

As of Q4 2022, Perceptive Advisors held 127 positions worth $3.56B, up 3.4% from $3.45B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Perceptive Advisors withdrew a net $205M in Q4 2022, closing 31 positions and reducing 25 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $158M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Perceptive Advisors opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares worth $109M.

  • Perceptive Advisors's largest Q4 2022 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 960,000 shares worth $109M.
  • Perceptive Advisors added most to Sarepta Therapeutics in Q4 2022, an estimated $45.9M increase.
  • Perceptive Advisors's biggest Q4 2022 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $38.4M.
  • Perceptive Advisors fully exited Global Blood Therapeutics, Inc. in Q4 2022, selling an estimated $158M.
  • Perceptive Advisors's ten largest holdings make up 46% of its $3.56B portfolio in Q4 2022.
  • Perceptive Advisors opened 13 new positions and closed 31 in Q4 2022.
  • Perceptive Advisors's portfolio value rose 3.4% quarter-over-quarter to $3.56B.

Based on Perceptive Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.